ArticleMetabolomics : Official journal of the Metabolomic Society2026
ILDMDB: a manually curated database of metabolite-disease associations in interstitial lung diseases.
Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionMetabolomics analysis shows great promise in identifying non-invasive biomarkers for interstitial lung diseases (ILDs). However, the relevant data are scattered across numerous disparate publications, hindering their full utilization.
objectivesTo comprehensively leverage the metabolomic data disseminated throughout the literature, we manually curated and integrated them into the ILDMDB database ( https://ildmdb.shinyapps.io/ILDMDB/ ). This database will be regularly updated and maintained.
methodsWe conducted a systematic literature search and extracted key metabolomics data, including changes in metabolites, relevant clinical parameters, and predictive model performance metrics etc. These data were then manually integrated into the ILDMDB database.
resultsThe current version of ILDMDB contains 3,969 entries, representing 20 ILD types and over 1,000 metabolites derived from Homo sapiens, animal models, and cell line experiments. Each entry comprises detailed information, including the metabolite name, disease type, and original reference. In addition, we have incorporated model data on metabolites used for ILD diagnosis, disease severity, and prognosis, along with information on metabolites associated with clinical parameters. Users can search for target metabolites freely, view their expression patterns and detailed information, and manage metabolite collections in the database.
conclusionILDMDB serves as an exploratory platform designed to assist researchers in swiftly and conveniently accessing the metabolic landscape of ILDs, thereby advancing research into the diagnosis, prognosis, and treatment of ILDs from a metabolic perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.